TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25245629
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with azathioprine
Study: 25247300
Drug: Meningococcal vaccines
Normalized name: Meningococcal vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal vaccines targeting fHbp
Study: 25248945
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (ARS) 100, 150, or 200 mg OD
Study: 25248945
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (ARS)
Study: 25250858
Drug: RO4929097 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO4929097 (20 mg daily, 3 consecutive days per week)
Study: 25253045
Drug: Oral panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral panobinostat (30 mg single dose for core phase, then thrice-weekly for extension phase)
Study: 25254044
Drug: NRT (30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT (30 mg of cocoa polyphenols, 80 mg of soy isoflavones, and 2 gr of myo-inositol)
Study: 25254563
Drug: Intraperitoneal catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal catumaxomab (10, 20, 50, and 150 μg within 10 days)
Study: 25260365
Drug: Estradiol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (6 mg/day for 3 months)
Study: 25260365
Drug: Low-dose estradiol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose estradiol treatment
Study: 25260365
Drug: Overall effectiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall effectiveness of treatment
Study: 25260842
Drug: tasisulam combined
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasisulam combined with 1,000 mg/m² gemcitabine HCl (days 1 and 15)
Study: 25260842
Drug: tasisulam combined
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasisulam combined with 60 mg/m² docetaxel
Study: 25260842
Drug: tasisulam combined
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasisulam combined with 200 mg/m²/day temozolomide
Study: 25260842
Drug: tasisulam combined
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasisulam combined with 75 mg/m² cisplatin
Study: 25260842
Drug: tasisulam combined
Normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasisulam combined with 150 mg/day erlotinib
Study: 25261424
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily with rifampicin thrice weekly
Study: 25261424
Drug: Raltegravir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 800 mg twice daily with rifampicin thrice weekly
Study: 25261716
Drug: Homemade bilayer
Normalized name: Welmedix Homecare Pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homemade bilayer adhesive patch (AOS)
Study: 25261839
Drug: Sofosbuvir and
Normalized name: sofosbuvir and ledipasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and ribavirin (400 mg) treatment for up to 48 weeks before liver transplantation
Study: 25262042
Drug: PST plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST plus antidepressant medications
Study: 25262042
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications alone
Study: 25262042
Drug: Overall depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall depression treatment
Study: 25264305
Drug: Crizotinib at
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib at the standard oral dose of 250 mg twice daily
Study: 25264981
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment (10 mg/Kg/day)
Study: 25264981
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and simultaneous exercise training
Study: 25267381
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for 6 months
Study: 25267562
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (silicone metacarpophalangeal arthroplasty - SMPA)
Study: 25267741
Drug: Glembatumumab vedotin
Normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glembatumumab vedotin (1.88 mg/kg every 3 weeks)
Study: 25267741
Drug: Glembatumumab vedotin
Normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glembatumumab vedotin (1.5 mg/kg dosing during 2 of 3 weeks)
Study: 25267741
Drug: Glembatumumab vedotin
Normalized name: Glembatumumab vedotin
DrugBank: Glembatumumab vedotin (DB05996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glembatumumab vedotin (1.0 mg/kg weekly)
Study: 25267759
Drug: Post-transplantation cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-transplantation cyclophosphamide (PTCy) at 50 mg/kg/day on post-transplantation days +3 and +4
Study: 25267955
Drug: Fecal calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal calprotectin (FC) levels > 30 µg/g
Study: 25267955
Drug: Combined test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined test using FC > 30µg/g and SIBDQ score < 6
Study: 25270430
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (5 g/day: 1.9-2.2 g EPA; 1.1 g DHA)
Study: 25270908
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (n = 121)
Study: 25271871
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) treatment
Study: 25272081
Drug: Oka-RIT (Varilrix™)
Normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka-RIT (Varilrix™) vaccine, 2 doses at 4.5 and 6.5 months post transplantation
Study: 25272081
Drug: Oka-RIT (Varilrix™)
Normalized name: ZOSTER VACCINE LIVE (OKA/MERCK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka-RIT (Varilrix™) vaccine
Study: 25273351
Drug: C-reactive protein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T
Study: 25273351
Drug: A score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A score combining 5 biomarkers (C-reactive protein, interleukin-6, tumor necrosis factor-α receptor II, pro-BNP, cardiac troponin T)
Study: 25274394
Drug: Augmentation Pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation Pressure (AP)
Study: 25274394
Drug: Heart Rate-Adjusted
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart Rate-Adjusted Augmentation Index (AI75)
Study: 25276415
Drug: Clonidine (4 µg/kg)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (4 µg/kg)
Study: 25276665
Drug: Darunavir (Prezista(®))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir (Prezista(®)) with low-dose ritonavir (DRV/r) 600/100 mg twice daily
Study: 25280062
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) enoxaparin at a standard dose of 1 mg/kg every 12 h
Study: 25281031
Drug: Copper histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copper histidine treatment (early treatment prior to onset of symptoms)
Study: 25281041
Drug: Old formulation
Normalized name: Poly Hist PD (old formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old formulation of UFH
Study: 25281041
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of UFH
Study: 25281041
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of UFH
Study: 25281400
Drug: Rifabutin dosed
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin dosed at 5 mg/kg three times a week
Study: 25283266
Drug: Axitinib at
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib at a starting dose of 5 mg b.i.d.
Study: 25284275
Drug: Adalimumab retreatment
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab retreatment (80 mg initial dose, followed by 40 mg every-other-week for 16 weeks)
Study: 25285126
Drug: MenACYW-D (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACYW-D (two doses at 12 and 18 months)
Study: 25285126
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup C conjugate vaccine (MCC, one dose at 12 months)
Study: 25285126
Drug: DTaP-IPV-Hib (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-Hib (administered concomitantly with MenACYW-D)
Study: 25285269
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with tiotropium for newly diagnosed COPD patients
Study: 25285572
Drug: No protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: No protease inhibitors (Control)
Study: 25286053
Drug: Rapamycin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin treatment before the first islet infusion; induction therapy with anti-thymocyte globulin (ATG); short-term treatment with steroids and interleukin-1Ra; maintenance therapy with rapamycin+mycophenolate mofetil
Study: 25286053
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with anti-thymocyte globulin (ATG)
Study: 25286173
Drug: β-lactam and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-lactam and macrolide combination treatment
Study: 25287822
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg per day plus capecitabine 1,500 mg/m2 per day
Study: 25288018
Drug: Weekly rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly rituximab consolidation (375 mg/m², four times infusion) after four cycles of R-CHOP21
Study: 25289522
Drug: Oseltamivir, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir, single 75 mg dose administered before APD treatment.
Study: 25290090
Drug: Bosutinib 300
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 300 mg once daily plus capecitabine 1000 mg m(-2) twice daily
Study: 25293768
Drug: Rituximab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (4 infusions of 375 mg/m²)
Study: 25293768
Drug: Rituximab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (2 fixed 1-g infusions 2 weeks apart)
Study: 25293773
Drug: Local radiotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local radiotherapy to solitary lymphoma nodes and intranodal injections of low-dose rituximab (5 mg), immature autologous dendritic cells, and granulocyte-macrophage colony-stimulating factor, repeated 3 times targeting different lymphoma nodes
Study: 25294897
Drug: Refametinib plus
Normalized name: Refametinib
DrugBank: Refametinib (DB06309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refametinib plus sorafenib (refametinib 50 mg twice daily, sorafenib 200 mg morning/400 mg evening, with possible escalation to 400 mg twice daily from cycle 2)
Study: 25295432
Drug: Antipsychotic-treated patients
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-treated patients
Study: 25295646
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) up to 70 mg/day for 5 weeks
Study: 25295646
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts-immediate release (MAS-IR) up to 45 mg/day for 5 weeks
Study: 25296762
Drug: Moderate-SFA reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-SFA reduction (3.68-13.67 g)
Study: 25296762
Drug: High-SFA reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-SFA reduction (>13.67 g)
Study: 25296762
Drug: Low-SFA reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-SFA reduction (<3.68 g)
Study: 25299251
Drug: Best treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best treatment options for dengue patients with refractory shock
Study: 25303490
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human chorionic gonadotropin (r-hCG) 25 μg iv administration
Study: 25304641
Drug: Sofosbuvir 400
Normalized name: sofosbuvir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily (adjusted according to creatinine clearance and hemoglobin values) for 24 weeks
Study: 25304729
Drug: IFN-α therapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α therapy (3 MU 3 times weekly)
Study: 25304853
Drug: Early aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early aspirin therapy
Study: 25305705
Drug: ACE inhibitor/angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor/angiotensin receptor blocker (ACEI/ARB)
Study: 25305705
Drug: Antihypertensive agent
Normalized name: Antihypertensive agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agent not affecting the renin angiotensin system (non-RAS)
Study: 25307711
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 5 ml/kg of Ringer's acetate intravenously for over 15 min
Study: 25308138
Drug: h-FABP above
Approvals — FDA: no, EMA: no, PMDA: no
Description: h-FABP above 6 μg/L
Study: 25308138
Drug: BNP >
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP > 100 pg/mL
Study: 25308138
Drug: cTnI-Ultra >
Approvals — FDA: no, EMA: no, PMDA: no
Description: cTnI-Ultra > 0.05 μg/L
Study: 25308138
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of h-FABP with PESI
Study: 25309090
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate (NaP) tablets, 4 tablets with 250 mL of water every 15 min, three times on the day of the procedure.
Study: 25312446
Drug: Antipsychotic polytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic polytherapy
Study: 25313095
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg every 2 weeks (with dose adjustments for weight)
Study: 25313914
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg recombinant-human chorionic gonadotropin
Study: 25314069
Drug: α-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-tocopherol (50 mg/day)
Study: 25314069
Drug: β-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-carotene (20 mg/day)
Study: 25314291
Drug: CC-carriers (n=20)
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-carriers (n=20)
Study: 25318437
Drug: Temsirolimus 25
Normalized name: temsirolimus 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 25 mg IV on Days 1, 8, 15, and 22 of a 28 day cycle and Bevacizumab 10 mg/kg IV on Days 1 and 15 of the cycle
Study: 25320340
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily)
Study: 25320355
Drug: Ridaforolimus (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus (10-40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week)
Study: 25320355
Drug: Ridaforolimus and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus and dalotuzumab combination
Study: 25322359
Drug: Frozen fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen fecal microbiota transplantation (FMT) capsules, 15 capsules administered on 2 consecutive days.
Study: 25323764
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH) therapy at a mean dose of 0.053 mg/kg/day over 3 years
Study: 25324973
Drug: 350 ng
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 ng aviscumine twice weekly by subcutaneous injection until progression
Study: 25327505
Drug: Amikacin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (20 mg/kg)
Study: 25327505
Drug: Amikacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (25 mg/kg)
Study: 25328681
Drug: PROSTVAC immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROSTVAC immunotherapy
Study: 25328711
Drug: Melatonin 6mg
Normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 6mg oral for 3 months
Study: 25329562
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid 25 mg daily for 2 weeks
Study: 25329821
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1200 mg as carbonate)
Study: 25330463
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg QD sc for 12 weeks
Study: 25331113
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m² plus liposomal doxorubicin 20 mg/m² (R-Dox) every 3 weeks
Study: 25331616
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2, intravenous, twice a week for 2 weeks, maximum of 8 cycles)
Study: 25332326
Drug: [(13)C5]5-formyltetrahydrofolate delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(13)C5]5-formyltetrahydrofolate delivered in a pH-sensitive enteric caplet (855 nmol / 400 μg)
Study: 25332326
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of [(13)C5]5-formyltetrahydrofolate (214 nmol)
Study: 25332483
Drug: 54 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 g/d LNS with milk protein base (milk-LNS)
Study: 25332483
Drug: 54 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 g/d LNS with soy protein base (soy-LNS)
Study: 25332483
Drug: 71 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 71 g/d corn-soy blend (CSB)
Study: 25335932
Drug: OSI-906 50
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI-906 50 mg BID; everolimus 5 mg QD
Study: 25335932
Drug: OSI-906 100
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI-906 100 mg BID; everolimus 10 mg QD
Study: 25335932
Drug: OSI-906 100
Normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSI-906 100 mg BID; everolimus 5 mg QD
Study: 25336464
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg IV infusion at baseline and on day 15)
Study: 25338318
Drug: Nintedanib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (oral, small-molecule tyrosine kinase inhibitor)
Study: 25338926
Drug: FPG ≥5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG ≥5.6 mmol/L
Study: 25338926
Drug: FPG combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG combined with A1C (FPG ≥5.6 mmol/L and/or A1C ≥5.7% [39 mmol/mol])
Study: 25340593
Drug: poly-L-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: poly-L-lactic acid
Study: 25340778
Drug: Combined antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiretroviral therapy (cART) for 8 months
Study: 25340784
Drug: GLP-1 agonist
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 agonist therapy
Study: 25342141
Drug: MEDI-573 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-573 (5 mg/kg, 15 mg/kg, 45 mg/kg on Day 1, 8, and 15 of 21-day cycles)
Study: 25343737
Drug: Interview survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interview survey tool about bullying administered to children
Study: 25344362
Drug: Trametinib and
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib and everolimus (daily dosing with both agents)
Study: 25344362
Drug: Trametinib and
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib and everolimus (daily dosing with trametinib and intermittent everolimus dosing)
Study: 25344536
Drug: Prolonged continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged continuous positive airway pressure (CPAP) therapy with supplemental oxygen